Interim data reported for abcellera-discovered covid-19 antibody in phase 2 clinical trials

Interim data from a phase 2 clinical trial of ly-cov555 shows a reduction in the rate of hospitalization in patients treated with the antibody.
GOVX Ratings Summary
GOVX Quant Ranking